Analyst assessments are out on Amgen’s second quarter performance, and the comments sent the Thousand Oaks biotech giant’s stock on an upward track. The notes to investors drew attention to the company’s struggling core business, but called its pipeline of new products “promising.” Shares are more than $10 higher after the company’s earnings report July…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
